Made in the UK
Collective data from major clinical trials have shown that treatment with a DPP-4i improves glycemic control by increasing insulin secretion from islet cells, lowering levels of HbA1c, reducing adipocyte size, and suppressing inflammation [47,48,49,50,51]
The background rate of pancreatitis in the general population, especially among people with obesity and type 2 diabetes who use these medications, is already elevated by the underlying conditions themselves
All semaglutide injections are subcutaneous preferred sites are the lower abdomen, outer thigh, and outer upper arm, rotating weekly to minimize local reactions
One of only two Fc-fusion triple agonists in Phase 2 (the other is MWN-101)